NRSN
HEALTHCARENeuroSense Therapeutics Ltd
Live · NASDAQ · May 9, Close
What's Moving NRSN Today?
No stock-specific AI insight has been generated for NRSN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.90
Fundamentals
Trading
NRSN News
20 articles- NeuroSense Announces Pricing of Insider-Led PIPE FinancingYahoo Finance·Apr 28, 2026
- NeuroSense Granted Brazilian Patent Covering PrimeC CompositionYahoo Finance·Apr 6, 2026
- NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value RequirementsYahoo Finance·Apr 3, 2026
- NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 31, 2026
- NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's ReadoutYahoo Finance·Mar 24, 2026
- /C O R R E C T I O N -- NeuroSense/Yahoo Finance·Mar 18, 2026
- JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological ActivityYahoo Finance·Mar 16, 2026
- PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific ConferenceYahoo Finance·Mar 9, 2026
- NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALSYahoo Finance·Feb 18, 2026
- NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC CompositionYahoo Finance·Feb 9, 2026
- NeuroSense Granted U.S. Patent for Treatment of Alzheimer's DiseaseYahoo Finance·Jan 21, 2026
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SABYahoo Finance·Jan 8, 2026
- NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 StudyYahoo Finance·Dec 22, 2025
- Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsightYahoo Finance·Dec 9, 2025
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026Yahoo Finance·Dec 4, 2025
- NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALSYahoo Finance·Nov 24, 2025
- NeuroSense to Host Investor Webinar on December 8, 2025Yahoo Finance·Nov 3, 2025
- NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease BiomarkersYahoo Finance·Oct 6, 2025
- Sector Update: Health Care Stocks Retreat Late AfternoonYahoo Finance·Sep 10, 2025
- NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived NeuronsYahoo Finance·Sep 10, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.90
Fundamentals
Trading
About NeuroSense Therapeutics Ltd
Neurosense Therapeutics Ltd (NRSN) is a pioneering clinical-stage biotechnology company committed to transforming the landscape of neurodegenerative disease treatment, particularly focusing on Parkinson's disease. Leveraging its proprietary development platform, Neurosense is advancing a robust pipeline of innovative therapeutic candidates currently in pivotal clinical trials, addressing substantial unmet medical needs in neurology. With a seasoned management team and strategic collaborations, the company is poised to deliver cutting-edge therapies that significantly improve patient outcomes and strengthen its position within the biopharmaceutical sector.